FP01

DRUG3 trials

Sponsors

Avalo Therapeutics, Inc.

Conditions

Acute CoughChronic Refractory CoughHealthy

Phase 1

A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

CompletedNCT01579526

Avalo Therapeutics, Inc.Healthy

Start: 2012-04-30End: 2012-05-31Updated: 2012-05-17

Phase 2

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

CompletedNCT01597349

Avalo Therapeutics, Inc.Acute Cough

Start: 2012-05-31End: 2012-09-30Updated: 2014-02-28

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

CompletedNCT01703923

Avalo Therapeutics, Inc.Chronic Refractory Cough

Start: 2012-11-30End: 2013-09-30Updated: 2014-11-05